BNP Paribas Financial Markets’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

BNP Paribas Financial Markets’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-150	Closed	-$767	–	4329
2022 Q1	$767	Buy	150 +1	+0.7%	+$6	﹤0.01%	3986
2021 Q4	$839	Hold	149	–	–	﹤0.01%	4068
2021 Q3	$1.65K	Sell	149 -30	-17%	-$377	﹤0.01%	3825
2021 Q2	$3.04K	Sell	179 -470	-72%	-$8.91K	﹤0.01%	3838
2021 Q1	$17K	Sell	649 -513	-44%	-$23.3K	﹤0.01%	3783
2020 Q4	$42K	Sell	1,162 -48	-4%	-$1.74K	﹤0.01%	3633
2020 Q3	$42.8K	Buy	1,210 +1,083	+853%	+$47.1K	﹤0.01%	3545
2020 Q2	$5.4K	Sell	127 -163	-56%	-$11K	﹤0.01%	3977
2020 Q1	$23.2K	Buy	290 +155	+115%	+$12.4K	﹤0.01%	3866
2019 Q4	$12.5K	Buy	135 +89	+193%	+$7.51K	﹤0.01%	4102
2019 Q3	$3.47K	Buy	46 +41	+820%	+$3.15K	﹤0.01%	4312
2019 Q2	$458	Buy	+5	New	+$387	﹤0.01%	4414

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BNP Paribas Financial Markets's EVFM Position: Q2 2022 in Review

BNP Paribas Financial Markets sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 150 shares — an estimated $767 sold.

BNP Paribas Financial Markets first reported a position in EVFM in Q2 2019 and held it in 12 quarters. The position peaked at $42.8K in Q3 2020. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

BNP Paribas Financial Markets reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
BNP Paribas Financial Markets sold 150 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $767.
BNP Paribas Financial Markets first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
BNP Paribas Financial Markets's Evofem Biosciences, Inc. Common Stock position peaked at $42.8K in Q3 2020.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2022, filed 12 Aug 2022.